IMPRiND Project

Charlotte Delay from Janssen wins Best poster at the IMI 10th Anniversary Symposium

At the IMI 10th anniversary scientific symposium, held on 22-23 October 2018 in Brussels, 72 posters and 25 oral presentations were selected to showcase young scientists from IMI projects. Charlotte Delay from Janssen Pharmaceuticals, was awarded first prize for her poster: "Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease". Abstract.

PostDoc position at Servier

Servier is looking for In vivo post-doctoral scientist in neurodegeneration to join their neuroscience department to work on animal models in Alzheimer’s and Parkinson’s disease. For more details see the complete job description.

Database on Funding Activities for Personalised Medicine (PM) Research Has Been Launched

The International Consortium for Personalised Medicine (ICPerMed) database, launched on 5 July 2018, gives an overview on the actions in the field of personalised medicine performed in the ICPerMed member states and may assist interested users in finding suitable funding opportunities and information about potential funders in their respective country and/or region.

The access to the data requires simple registration here.

The first ICPerMed Conference ‘Personalised Medicine in Action’ will take place on 20-21 November 2018 in Berlin, Germany. Registration is now open.

Sources: ICPerMed, Euresearch

Two IMPRiND researchers win Brain prize! Congratulations!

The Brain Prize 2018 is awarded to Bart De Strooper, Michel Goedert, Christian Haass and John Hardy.

The efforts of these four leading scientists to understand Alzheimer's disease have provided the foundation for treatment of one of the most devastating diseases.

For this, they are receiving the world’s most valuable prize for brain research, The Lundbeck Foundation Brain Prize, worth 1 million euros.

Bart De Strooper and Michel Goedert are part of the IMPRiND consortium, we are proud to have them on board! Congratulations!


Innovative Medicines Initiative (IMI): evaluations of IMI1 and IMI2

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;

- the quality of the research emerging from IMI projects;

- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation

Read the new IMI brochure on results and impacts

Source: IMI

Show more posts

This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116060. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 17.00038.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.